Article Text

Download PDFPDF
Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with atrial fibrillation (AF) at risk for ischaemic stroke, is ximelagatran non-inferior to warfarin in preventing stroke and systemic embolism?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Internal medicine ★★★★★★★ Cardiology ★★★★★★☆ Haematology ★★★★★★★


Embedded ImageDesign:

randomised controlled trial (Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation [SPORTIF]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (outcome assessors).*

Embedded ImageFollow up:

mean 17.4 months.

Embedded ImageSetting:

259 hospitals, doctor’s offices, and clinics in 23 countries.

Embedded ImagePatients:

3410 patients ⩾18 years of age who had nonvalvular AF and ⩾1 additional risk factor for stroke: treatment for hypertension but blood pressure <180/100 mm Hg; age ⩾75 years; previous stroke, transient ischaemic attack (TIA), or systemic embolism; left ventricular dysfunction; or age …

View Full Text


  • * See glossary.

  • For correspondence: Professor S B Olsson, University Hospital, Lund, Sweden.

  • Source of funding: AstraZeneca.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd